Brandon DeKosky Joins American Lung Association COVID-19 ACTION Initiative
-from the ALA press release linked below-
"As the COVID-19 pandemic reached the United States, the American Lung Association announced the COVID-19 Action Initiative, designed to accelerate the search for COVID-19 solutions. Through this initiative, the organization announced a new research award, immediately expanded its existing research clinical trial infrastructure to include COVID-19 research and placed an urgent call for applications for the most promising research studies on COVID-19. Today, the American Lung Association announced the 12 new COVID-19 research award recipients.
The awardees for the inaugural COVID-19 and Respiratory Virus Research Award are funded at $100,000 a year for two years. This award explores important avenues to find better treatments to reduce the burden we have experienced due this virus:
- Tishra Beeson, DrPH, MPH, Central Washington University: Keys to prevention – reducing community spread of COVID-19 in vulnerable communities
- Stephen Chan, M.D., Ph.D., University of Pittsburgh: NCOA7 as a novel therapeutic and genetic diagnostic target in SARS-CoV-2 infection
- *Brandon DeKosky, Ph.D., University of Kansas: Molecular analysis of antibody responses associated with COVID-19 respiratory distress*
- Marta Maria Gaglia, Ph.D., Tufts University: Control of innate immune responses by SARS-CoV-2
- Marcia Goldberg, M.D., Massachusetts General Hospital: High resolution definition of the pathogenic immune response in ARDS during COVID-19 infection
- Dan Jane-Wit, M.D., Ph.D., Yale University: The role of ZFYVE21 in COVID-19 respiratory complications
- Sharon Morley, M.D., Ph.D., Washington University in St. Louis: COVID-19 infection, NLRP3 inflammasome activation and therapeutic trials to treats ARDS in mouse model
- Irina Petrache, M.D., National Jewish Health: Novel risk factors for severe COVID-19 lung disease
- Kurt Randall Stenmark, M.D., University of Colorado: Role of hypoxia and complement in lung endothelial cell injury in COVID-19
- Daniel Weiss, M.D., Ph.D., University of Vermont: Mechanisms of SARS-CoV-2 induced type 2 alveolar epithelial cell pathogenesis
- Andrew A. Wilson, M.D., Boston University: Defining the alveolar epithelial response to SARS-CoV-2 and additional risk of cigarette smoke or e-cigarette vapor exposure
- Gary A. Weisman, Ph.D., University of Missouri: P2Y2 receptor-integrin interactions in Spike- and ACE2-mediated SARS-CoV-2 entry in lung alveolar epithelial cells"
We wish Dr. DeKosky and the team all the best as they work to develop solutions to this crazy pandemic!